

9. The compound or salt according to any one of Claims 1-7 for use in therapy.

10. The compound or salt according to any one of Claims 1-7 for use in the treatment of cancer.

11. The compound or salt for use according to Claim 10 wherein the cancer is
5 selected from the group consisting of melanoma, colorectal cancer, pancreatic cancer, and non-small cell lung cancer.

12. The compound or salt for use according to Claim 11, wherein the cancer is colorectal cancer.

13. The compound or salt for use according to Claim 11, wherein the cancer is
10 pancreatic cancer.

14. The compound or salt for use according to Claim 11, wherein the cancer is non-small cell lung cancer.

15. A combination comprising a compound or salt thereof according to Claim 7 and ramucirumab for simultaneous, separate, or sequential use in the treatment of non-
15 small cell lung cancer.

16. A compound or salt thereof according to Claim 7 for use in simultaneous, separate or sequential combination with ramucirumab in the treatment of non-small cell lung cancer.

17. Use of ramucirumab in the manufacture of a medicament for the treatment
20 of non-small cell lung cancer, wherein the ramucirumab is to be simultaneously, separately, or sequentially combined with a compound or salt thereof according to Claim 7.

18. The combination, compound or salt thereof for use according to Claim 15 or 16, or use according to Claim 17, wherein the non-small cell lung cancer is KRAS
25 mutant non-small cell lung cancer.

19. A combination comprising a compound or salt thereof according to Claim 7 and [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, for simultaneous, separate, or sequential use in the treatment of non-small cell lung cancer.

20. A compound or salt thereof according to Claim 7 for use in simultaneous, separate or sequential combination with [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in the treatment of non-small cell lung cancer.

21. Use of [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of non-small cell lung cancer, wherein the [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine is to be simultaneously, separately, or sequentially combined with a compound or salt thereof according to Claim 7.

22. The combination, compound or salt thereof for use according to Claim 19 or 20, or use according to Claim 21, wherein the non-small cell lung cancer is KRAS mutant non-small cell lung cancer.

23. A combination comprising a compound or salt thereof according to Claim 7 and [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, for simultaneous, separate, or sequential use in the treatment of colorectal cancer.

24. A compound or salt thereof according to Claim 7 for use in simultaneous, separate or sequential combination with [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in the treatment of colorectal cancer.

25. Use of [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the

treatment of colorectal cancer, wherein the [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine is to be simultaneously, separately, or sequentially combined with a compound or salt thereof according to Claim 7.

- 5 26. The combination, compound or salt thereof for use according to Claim 23 or 24, or use according to Claim 25, wherein the colorectal cancer is KRAS mutant colorectal cancer.